Table 2.
Variable | AIM (n=31) | Community Care (n=25) |
---|---|---|
Age, mean (SD) | 9.3(1.6) | 9.4(1.5) |
Male (%) | 20(65%) | 19(76%) |
Racial/ethnic minority (%) | 12(39%) | 9(36%) |
IQ, mean (SD) | 100.6(15.4) | 100.7(10.6) |
Entry Stimulant dose mg/kg/daya (SD) | .90(.40) | .90(.43) |
Using outside counseling services (%) | 18(58%) | 15(60%) |
Conduct disorder (%) | 4(13%) | 1(4%) |
Oppositional defiant disorder (%) | 29(94%) | 24(96%) |
Anxiety Disorders/Subthreshold Anxietyb (%) | 9(29%) | 11(44%) |
Elevated parental ADHD symptoms (ASRS) (%) | 17(55%) | 7(28%) |
Elevated parental depressive symptoms (BDI)(%) | 9(29%) | 7(28%) |
Socioeconomic Index, c mean (SD) | 42.3(15.2) | 42.03(12.8) |
Note: ADHD = attention-deficit/hyperactivity disorder; AIM = Novel therapy for ADHD plus Impairments in Mood; ASRS = Adult ADHD Self-Report Scale; BDI = Beck Depression Inventory
In methylphenidate equivalents on a mg/kg/day basis.
Anxiety symptoms assessed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children: Present and Lifetime version (K-SADS-PL).
Based on Nakao and Treas (1994).